Yang Cao - 08 Dec 2023 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Role
Chief Regulatory Officer
Signature
/s/ Yang Cao by Dale A. Sander as Attorney-in-Fact
Issuer symbol
HUMA
Transactions as of
08 Dec 2023
Transactions value $
$0
Form type
4
Filing time
12 Dec 2023, 16:09:57
Previous filing
20 Sep 2022
Next filing
23 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HUMA Stock Options (right to buy) Award $0 +210K $0.00 210K 08 Dec 2023 Common Stock 210K $2.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The first 25% of the option becomes exercisable on December 8, 2024, after which 1/48 of the option will become exercisable on the 8th of each month through December 8, 2027.